Business Context and Reporting Period
This Form 8-K, filed on November 9, 2006, reports a material definitive agreement entered into by Abbott Laboratories on November 5, 2006. The filing details the commencement of a tender offer to acquire Kos Pharmaceuticals, Inc. ("Kos") through a wholly-owned subsidiary, Parthenon Acquisition Corp.
Key Financial Metrics and Transaction Terms
- Purchase Price: $78.00 per share in cash for all outstanding Kos shares.
- Transaction Structure: A tender offer followed by a merger of the acquisition subsidiary into Kos.
- Controlling Interest Commitment: The Jaharis family shareholders (controlling approximately 53% of Kos shares) have committed to tender their shares.
- Specific Agreements:
- Shareholders Agreement: Covers approximately 35% of outstanding Kos shares owned by the Jaharis family.
- Stock Purchase Agreement: Abbott agreed to purchase 100% of Kos Investments, Inc., which owns approximately 18% of Kos shares. The price equals the cash offer value minus Kos Investments' liabilities.
Note: This filing does not provide Abbott Laboratories' consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a transaction-specific report.
Material Changes and Conditions
The primary material change is the initiation of the acquisition process for Kos Pharmaceuticals. The consummation of the offer and merger is subject to customary closing conditions, including:
- Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Acquisition of a majority of Kos shares.
- Continued recommendation by the Kos Board of Directors (unless withdrawn, in which case a majority of non-Jaharis shares must be tendered).
Outlook, Risks, and Contingencies
Abbott cautions that the tender offer may not be completed or the merger may not be consummated if conditions precedent are not satisfied. The filing references forward-looking statements subject to risks including economic, competitive, governmental, and technological factors. These risks are detailed in Abbott's 2005 Form 10-K and 2006 Form 10-Q. Abbott undertakes no obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the final tender offer statement and related solicitation documents once filed with the SEC.
- Confirm the status of the Hart-Scott-Rodino antitrust waiting period.
- Monitor for any withdrawal of the Kos Board of Directors' recommendation of the offer.
- Review the specific liabilities of Kos Investments, Inc., which will reduce the purchase price for that specific stake.